The clinical effects of combination chemotherapy with five or six anticancer drugs were investigated on the patients with the advanced cancer which originated mainly from the gastrointestinal tract.
(67%).
The incidence of the cases which showed favorable clinical responses was higher in the five and six-drug regimens than in the one-, two-and three-drug regimens.
Leukopenia, which occurred in almost half of the patients, was observed more frequently in cases of the six-drug regimen than in cases of the five-drug regimen. Gastrointestinal disturbances were found frequently during and after treatment, and seemed to be aggravated mainly by 5-FU and SP-G in these regimens. The main reasons for the discontinuation of these therapies were firstly leukopenia and secondly gastrointestinal upsets.
The cases treated with the five or six-drug regimen survived only slightly longer than the non-treated.
However, there were few remarkable differences in the survival period between the cases of the five or six-drug regimen and the cases of other regimens. The patients with cancer at various sites were assigned at random to either of the above two regimens.
The distribution of patients according to the site of primary tumor is shown in Tables 2 and 3 . Twenty-seven patients (16 males and 11 females) were assigned to the five-drug regimen and 58 patients (34 males and 24 females) to the six-drug regimen . Most of the patients were in inoperable stage or postoperative relapse stage of cancer , of which the diagnosis was established by pathological examination of surgical specimens and by postmortem autopsy.
Some of the patients in non-relapse stages immediately after operation were also treated with these regimens. Namely, the drugs were administered as an adjuvant therapy in addition to radical surgery. The chemotherapy was discontinued when severe toxic side-effects such as anorexia, nausea, vomiting, diarrhea and leukopenia (below 3,000/mm3) developed and deteriorated the general condition of the patients.
The clinical effects of these treatments were evaluated according to our criteria,3 as shown in Table 4 , with the numerical grading system based on subjective symptoms and objective findings. On admission each positive subjective or objective symptom is counted as 3 points and then multiplied by the total number of symptoms presented by the patient. This number denotes the index of the clinical symptoms on admission. Successive indexes are next obtained whenever changes occur in the symptoms during the subsequent clinical course by adding the point given to each symptoms according to the criteria given below. The relative degrees of improvement or aggravation throughout the entire course can thus be represented by curve (clinical curve). The results obtained were discussed in comparison with the results of chemotherapy of solid tumors with the one-, two-or three-drug regimen which were previously reported.4-6 the degree of aggravation in the 4th week is over 3.5 Unchanged:
the degree of change in the 4th week is between 2.5 and 3.5 Effective:
the maximum improvement is between 1.5 and 2.5 Markedly effective: the maximum improvement is below 1. 5 (Compare with the clinical curve)
RESULTS
The frequency of administration and the total dose of each drug are shown in Table 5 . On an average, MMC was administered 7.9 times and the other drugs were administered for about 4 weeks in both the five-and six-drug regimens. As reported previously,4-6 MMC has been used most frequently as the major drug in the combination chemotherapy and given usually in a dose of 6mg twice a week in the one-, two-and three-drug regimens. The average dose of MMC was 48.0mg in the one-drug regimen, 39.5mg in combination with Ps, and 83.6mg in com bination with Ps and CHS. Therefore, the average total doses of MMC in the five and six-drug regimens, 47.3mg and 43.6mg respectively, were not much smaller than that in the two-drug regimen in combination with Ps.
Clinical response
The clinical effects of the treatments against various types of tumors are given in Tables 2 and 3 . One case in the five-drug regimen and 5 cases in the six -drug regimen were excluded from the clinical evaluation, as well as the cases who received an adjuvant chemotherapy immediately after operation, because these cases were considered inadequate for final evaluation. Of 21 cases in the five-drug regimen, only 1 case (5%) was considered to be markedly effective, 3 cases (14%) effective, 11 cases (52%) unchanged, and 6 cases (29%) ineffective. Of 43 cases in the six-drug regimen, 2 cases (5%) were considered to be markedly effective, 11 cases (25%) effective, 16 cases (37%) unchanged, and 14 cases (33%) ineffective. Because it is considered that the unchanged cases also showed some favorable clinical responses to the treatment, the total number of patients who responded favorably to these therapies were 15 of 21 patients (71%) in the five-drug regimen and 29 of 43 patients (67%) in the six-drug regimen. The effects of these regimens are summarized in Table 6 together with those of other various anticancer drug regimens which were previously investigated. In the previous report,4-6 three regimens (MMC alone and two-or three-drug regi men) were also allocated at random to the patients in the advanced stage of cancer at various sites, and the clinical effects were evaluated by the same criteria as those in the present study. The results were compared with those of the five-and six -drug regimens. In cases of one-drug regimen, MMC was most effective. The favorable clinical responses occurred in 14 of the 28 patients (50%) treated with MMC alone, 17 of 40 patients (43%) treated with the two-drug regimen and in 15 of 29 patients (52%) treated with the three-drug regimen. It is evident from the above results that the efficacy of the five-and six-drug regimens was more remarkable than that of the other regimens. It is noticeable that the patients with stomach cancer, which is generally known to be drug resistant, showed a good response to the treatment with the five-and six-drug regimens.
Improvement of subjective symptoms and objective findings
The clinical results of the five-and six-drug regimens are shown in Tables  7 and 8 . On an average, about one-third of the total subjective symptoms such as dysphagia, lack of sensation of being well, cough, sputum, abdominal discomfort, anorexia, nausea, vomiting, pain, abdominal inflation and general fatigue were improved after therapy in both the five-and six-drug regimens, and the improve ment of the objective findings (alleviation of abnormally elevated body temperature, •õ Sum of denominator.
slowing down of blood sedimentation rate, a regression in the size of primary or metastatic tumor lesions, diuresis, an increase of vigor, a decrease in the quantity of peritoneal and pleural effusions, disappearance of edema and gain of weight) was also observed in about one-third of the total in each regimen. As is evident from Table 9 , there were no differences in the rate of improve ment of the subjective symptoms between various regimens. In contrast, more excellent improvement of the objective findings was obtained with the five-and six- •õ Sum of denominator. drug regiems than with MMC alone or in combination with Ps or with other two drugs. A regression in the size of primary or metastatic tumor lesions, which represented the most direct effect of anticancer agents, was observed in 8 of 34 lesions (24%) in cases of the five-drug regimen and in 7 of 31 lesions (23%) in cases of the six-drug regimen.
Toxic side-effects
Side-effects except for those on hematopoietic organs were examined in 27
patients treated with the five-drug regimen and in 52 patients treated with the six-drug regimen. In these two regimens, postoperative cases which received an adjuvant chemotherapy were also included. The incidence of drug toxicity by these combination therapies is shown in Table 10 . Among various side-effects, gastrointestinal disturbances were the main symptom. Especially, diarrhea, which was the commonest symptom but not so severe, developed in 6 patients (22%) treated with the five-drug regimen and in 21 patients (40%) treated with the six-drug regimen. It was assumed that gastrointestinal disturbances such as diarrhea, abdominal discomfort, nausea and vomiting were aggravated mainly by 5-FU, SP-G and/or Azetepa in these regimens. However, there were no cases with ulcerative stomatitis and esophagitis, although these serious complications were frequently observed during therapy with 5-FU alone. This may be ascribed to the fact that the dose of 5-FU was relatively low in these regimens. The toxic manifestations of the skin or nervous system such as epilation, dermatitis and headache were not found during the treatment. The toxic involvement of the liver was observed in one patient with lung cancer treated with the six-drug regimen, but it subsided promptly after the drugs were withheld. The renal function was tested by urinalysis and the determination of PSP excretion, blood NPN and serum electrolyte concentration, but no disturbance was found in any cases during and after the treatment. The toxic effect on hematopoietic organs is a serious problem in chemotherapy against cancer. Figs. 1 and 2 show the fluctuations in the number of white blood cells caused by the five-and six-drug regimens. Leukopenia occurred rapidly after the initiation of the treatment in both the five-and six-drug regimens, although the white blood cells seemed to decrease in number more quickly with the six-drug regimen than with the five-drug regimen.
When 3,000 WBC/min3 were taken as the upper limit of leukopenia, marked leukopenia was observed more frequently in the patients treated with the six- drug regimen (59%) than in the patients treated with the five-drug regimen (41%) as shown in Table 11 . The total dose of MMC administered to the patients with leukopenia showing the minimum WBC count below 3,000/mm3 was some what larger in the five-drug regimen (49.6mg) than in the six-drug regimen (47.7mg). The distribution of the minimum WBC count observed in the patients after therapy was examined in relation to the toal dose of given MMC. As shown in Table 12 , the total dose of given MMC was classified into four grades. The percentage of the patients with the minimum WBC count below 3,000/mm3 increased in parallel with the total dose of given MMC. When a comparison was made between the regimens with the same amount of MMC, leukopenia seemed to occur more frequently in cases of the six-drug regimen than in cases of the five -drug regimen. This may be due to Azetepa, which was included only in the six -drug regimen. The number of thrombocytes showed nearly the same fluctuation as that of the white blood cells. Reasons for interruption of the five and six-drug regimens Table 13 shows the reasons why the five and six-drug regimens were discon tinued. Leukopenia was the main reason for the discontinuation in more than half of the cases in which treatment was interrupted. In some cases, the therapy was stopped because of severe gastrointestinal disturbances and hepatic dysfunction. Survival period in cases with the five-and six-drug regimens
As shown in Table 14 , the average survival period in the patients treated with the five-drug regimen was 11.7 months from the onset of the diseases, 4.9 months after admission, and 3.1 months after initiation of chemotherapy. On the other hand, the above periods in the patients treated with the six-drug regimen were 11.3, 5.1 and 3.6 months, respectively. The patients treated with the five-or six-drug regimen survived only slightly longer than the non-treated. However, there were few remarkable differences between the survival periods in cases of the five-or six-drug regimen and those in cases of the other drug regimens. Therapeutic synergism by combination of two anticancer drugs has been investigated extensively by Goldin and his co-workers7,8 in an experiment on mice with leukemia L 1210 model system. Theories such as sequential blocking,9 concurrent blocking10 and complementary blocking11 have been proposed for the explanation of biochemical mechanism in combination chemotherapy with two drugs. Frei12 stated that the major basis for combination chemotherapy in the clinic was related to independent toxicity, because the combination of agents with independent toxicity might produce a broader spectrum of toxicity, but might not produce an additive increase in serious dose-limiting toxicity. On the basis of these reports, the combination chemotherapy against cancer has been attempted by many clinical investigators to obtain enhanced antitumor effect without increasing toxicity. It would be desirable that the drugs with different modes of action on tumor cells and independent toxic effect on host should be chosen in the schedule of combination chemotherapy.
It is accepted that the quadruple combination therapy (VAMP) designed by Freireich et al. 13 showed more remarkable effect on acute lymphoctytic leukemia in childhood than the treatment by a single agent. In 1960, Li14 described that better therapeutic results for solid tumors were obtained by combination chemo therapy with Amethopterin, Chlorambucil and Actinomycin D than with each of these drugs. Since then, many clinical investigations15-22 have been carried out on combination chemotherapy of solid tumors. More recently, Nathanson et al. 23 reviewed relevant papers and reported their own experiences. In our country, the combination chemotherapy has also been attempted by many investigators.24-32 Kimura et al. [25] [26] [27] [28] and Konda30 observed an increase in the rate of tumor regression by the combination therapy named "FAMT" method. According to Ota,31,32 objective response was more freqeuently observed in the patients treated with "METT" method than in these treated with each drug. The results obtained in the present authors' work also indicate that the combination chemotherapy with the five-or six-durg regimen produced more remarkable clinical response than MMC alone, and two-and three-drug regimens. However, there was no marked difference in the rate of clinical response between the five-and six-drug regimens.
Goldin et al.33 reported a methodology for investigating the therapeutic efficacy of 3-way drug combination in animal experiment using the combination of Cyclophosphamide, Amethopterin and TIC, or of Cyclophosphamide, Ametho pterin and BCNU.
They stated that there was no clear evidence of therapeutic synergism. Other informations18,21,34-36 indicated that the rate of tumor regression was almost the same between the combination chemotherapy and the single chemotherapy and that antitumor effect of combination chemotherapy was not greater than that of single chemotherapy. Nathanson et al.23 also stated in their latest paper that relatively drug sensitive tumors may well have a marked augmentation of rate and/or quality of response to combination chemotherapy, but relatively insensitive tumors showed no favorable response to combination chemotherapy. Therefore, further studies are needed on the choice of agents and the schedule of administration in the combination chemothrapy.
As regards corticosteriod, Prednisolone has been employed by the present authors in combination with other anticancer drugs. Several reports are available on the use of corticosteroid in the treatment of cancer. However, it remains still undetermined whether the combined regimen with corticosteroid is advantageous for the treatment of cancer.37-42 According to our animal experiments43 using Donryu-rats inoculated with Yoshida-sarcoma, there was no evidence of an increase of metastases formation and acceleration of tumor growth in rats treated with anticancer drugs including Ps as compared with the rats treated with anti cancer drug alone. Various pathophysiological changes of the tumor-bearing rats, such as a decrease of serum cholinesterase activity, serum iron and serum protein, and an increase of serum LDH activity and serum mucoprotein, returned to normal more rapidly in the groups which received anticancer drugs including Ps than in the groups which received anticancer drug alone. Our clinical observation4 showed that a decrease of WBC count following administration of anticancer drugs could be prevented to some extent and also palliative response occurred frequently when the patients were treated with the anticancer drug regimen including Ps. Therefore, if some drugs with potential antitumor effect are to be used, Ps is worthy of consideration for the treatment of cancer in combination with anticancer drugs.
The most serious side effect caused by the five or six-drug regimen was leukopenia which was observed in almost half of the patients. Apart from the hematological changes. another serious side effect was gastrointestinal upsets mainly due to SP-G and 5-FU in these regimens. Attempts were made to relieve these side effects by using vitamins and glutathione concurrently. However, the results were not so satisfactory as to allow any discussion on this problem.
Finally, the efficacy of chemotherapy should be evaluated by the survival period of the patients. The survival period from the initiation of chemotherapy was longer in the patients on "FAMT" therapy than in those treated with MMC alone.30 A similar result with "METT" therapy was reported by Ota.31,32 However, the prolongaton of survival period by chemotherapy was not so clearly demonst rated in the patients with solid tumors as in those with leukemias. In our clinical study44 of 135 patients with gastrointestinal cancer in the advanced stage, 35 died within one month, 53 within one to three months, 26 within three to six months after the initiation of chemotherapy, and only three patients survived for a year or more. Namely, 85% of these patients died within six months. As mentioned above, the average survival period of the patients treated with the five -or six-drug regimen was only slightly longer than that of the non-treated. How ever, no significant difference was found in the survival period between the five-or six-drug regimen and other drug regimens.
In chemotherapy against cancer, it is important to keep the general condition of the patient as well as possible by taking the fluctuation in pathophysiological findings into consideration,4 and the choice of adequate drugs and the schedule and route of administration in the combination chemotherapy against cancer await further studies. 
